GlassScriptPhysician profile
Chinglin L Chan
NPI 1558354514
$7,042.92
in general payments reported to CMS, 2019-2025
38 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $1,218 · 2021: $1,002 · 2022: $1,126 · 2023: $825 · 2024: $1,504 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,619.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,012.92 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $866.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $855.74 | 2019-2022 | |
| Novo Nordisk INC | $789.25 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $503.16 | 2021-2025 | |
| Pfizer INC. | $371.34 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $310.00 | 2019-2025 | Breztri, Airsupra |
| Kowa Pharmaceuticals America, INC. | $290.78 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Radius Health, INC. | $232.42 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.20 | 2019-2023 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $175.03 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $160.18 | 2021-2024 | Qulipta, Ubrelvy, Vraylar |
| Alcon Vision LLC | $136.21 | 2022 | |
| Merck Sharp & Dohme LLC | $120.03 | 2019-2022 | |
| Astellas Pharma US INC | $107.98 | 2019-2024 | Veozah |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chinglin Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.